About neurocrine bios - NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
NBIX At a Glance
Neurocrine Biosciences, Inc.
6027 Edgewood Bend Court
San Diego, California 92130
| Phone | 1-858-617-7600 | Revenue | 2.86B | |
| Industry | Biotechnology | Net Income | 478.60M | |
| Sector | Health Technology | 2025 Sales Growth | 21.449% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,000 | |
| View SEC Filings |
NBIX Valuation
| P/E Current | 25.729 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 30.375 |
| Price to Sales Ratio | 5.082 |
| Price to Book Ratio | 4.364 |
| Price to Cash Flow Ratio | 18.57 |
| Enterprise Value to EBITDA | 20.295 |
| Enterprise Value to Sales | 4.729 |
| Total Debt to Enterprise Value | 0.035 |
NBIX Efficiency
| Revenue/Employee | 1,430,250.00 |
| Income Per Employee | 239,300.00 |
| Receivables Turnover | 4.165 |
| Total Asset Turnover | 0.665 |
NBIX Liquidity
| Current Ratio | 3.393 |
| Quick Ratio | 3.301 |
| Cash Ratio | 1.991 |
NBIX Profitability
| Gross Margin | 98.179 |
| Operating Margin | 22.251 |
| Pretax Margin | 24.66 |
| Net Margin | 16.731 |
| Return on Assets | 11.13 |
| Return on Equity | 16.383 |
| Return on Total Capital | 12.85 |
| Return on Invested Capital | 14.258 |
NBIX Capital Structure
| Total Debt to Total Equity | 14.488 |
| Total Debt to Total Capital | 12.654 |
| Total Debt to Total Assets | 9.915 |
| Long-Term Debt to Equity | 12.766 |
| Long-Term Debt to Total Capital | 11.151 |